📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. (2017)

First Author: Taylor SJ

Attributed to: Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.aam8060

PubMed Identifier: 28794285

Publication URI: http://europepmc.org/abstract/MED/28794285

Type: Journal Article/Review

Volume: 9

Parent Publication: Science translational medicine

Issue: 402

ISSN: 1946-6234